Alignment Healthcare Faces Financial Manipulation Allegations and Investigation

A whistleblower lawsuit has triggered a wave of securities-law investigations into ALHC, with a former executive alleging the Medicare Advantage insurer manipulated its accounting to inflate profitability metrics. The stock plunged roughly 16.7% in a single session this week, its worst one-day decline since February 2024, after the allegations became public.

The suit, filed by former chief transformation officer Hakan Kardes in U.S. District Court for the Central District of California, alleges Alignment misclassified certain operating expenses as capital expenditures, a move that would artificially inflate its adjusted EBITDA for 2024 and 2025. Kardes claims he raised the accounting concerns internally in May 2025 and was later forced to resign. Alignment has pushed back, saying an independent accounting firm it retained to review the claims concluded they were unfounded; the company calls the allegations "wholly without merit" and says it intends to defend itself vigorously. The episode has nonetheless drawn a string of plaintiffs'-side securities firms, including Block & Leviton , Johnson Fistel , and Hagens Berman , each soliciting investors who may have suffered losses to explore potential securities-fraud claims.

The allegations surface as Medicare Advantage insurers face heightened investor scrutiny over expense classification and risk-adjustment practices tied to CMS reimbursement. Alignment is scheduled to report second-quarter 2026 results and host a conference call on July 30, 2026, a print that will now double as a referendum on management's credibility as much as its underlying growth metrics. Investors will be watching for any restatement risk, commentary on the pending litigation, and whether the company reaffirms or walks back prior EBITDA guidance.

Related Stocks

• ALHC